Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
PBX1
REST API REST API
Homo sapiens
PBX1 is differentially expressed in 357 experiments: 164 organism parts: liver, bone marrow, ... (162 more);, 271 disease states: normal, control, ... (269 more);, 119 cell types 558 cell lines 39 compound treatments and 87 other conditions.
Orthologs Q4H2Y7_CIOIN (Ciona intestinalis)   PBX1 (Bos taurus)   Pbx1 (Rattus norvegicus)   F1NQJ4_CHICK (Gallus gallus)   exd (Drosophila melanogaster)   Pbx1 (Mus musculus)   pbx1a (Danio rerio)   PBX1 (1 of 2) (Danio rerio)   pbx1 (Xenopus laevis)   ENSCAFG00000013289 (Canis familiaris)   ENSCAFG00000025028 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term DNA binding, protein binding, regulation of transcription, DNA-dependent, cytoplasm, regulation of cell proliferation, transcription, DNA-dependent, positive regulation of cell proliferation, proximal/distal pattern formation, transcription factor binding, cell differentiation, steroid biosynthetic process, sequence-specific DNA binding, sex differentiation, positive regulation of transcription from RNA polymerase II promoter, nucleus, protein heterodimerization activity, transcription factor complex, organ morphogenesis, embryonic hemopoiesis, embryonic organ development, urogenital system development, branching involved in ureteric bud morphogenesis, adrenal gland development, regulation of ossification, embryonic skeletal system development, spleen development, negative regulation of neuron differentiation, thymus development, embryonic limb morphogenesis, sequence-specific DNA binding transcription factor activity, negative regulation of sequence-specific DNA binding transcription factor activity, anterior/posterior pattern specification
InterPro Term PBX, Homeobox
UniProt Accession Q53YC7, B7Z774, P40424, Q68DD6, B1ANF4, B1AN71, F5H4U9, F8WA05
Search EB-eye ENSG00000185630
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-6573, E-GEOD-1577, E-GEOD-7224, ... (32 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, ... (48 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-20081, E-GEOD-3529, E-GEOD-19639, E-GEOD-5823
BT474
3
E-MTAB-37, E-MTAB-62, E-MEXP-440
SW480
3
E-GEOD-18005, E-MEXP-1014, E-MTAB-37
LNCaP
2
E-GEOD-14464, E-GEOD-14990
A549
2
E-GEOD-6013, E-GEOD-3202
HCC1954
2
E-GEOD-29119, E-MTAB-37
552 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-21668, E-GEOD-3920, E-MEXP-750, E-GEOD-20677, ... (58 experiments)

Factor Value U/D Experiments
stromal cell
5
E-MEXP-2034, E-GEOD-1460, E-GEOD-3998, E-GEOD-10797, E-MEXP-1327 ... (5 experiments)
embryonic stem cell
2
E-MEXP-930, E-GEOD-2248
endothelial cell
1
2
E-GEOD-19240, E-GEOD-3920, E-GEOD-3998
pro B cell
1
E-MEXP-1403
testis - germ cell
1
E-AFMX-5
CD105+ endothelial
2
1
E-AFMX-5
113 more value(s).


Disease state

studied in E-GEOD-3307, E-MEXP-1121, E-GEOD-1577, E-TABM-15, E-GEOD-16363, ... (70 experiments)

Factor Value U/D Experiments
lung adenocarcinoma
3
E-MTAB-37, E-GEOD-2514, E-MTAB-62
melanoma
3
E-MTAB-62, E-MTAB-37, E-GEOD-7307
control
2
4
E-GEOD-21912, E-GEOD-16363, E-GEOD-20295, E-GEOD-16728, E-GEOD-20602, ... (6 experiments)
dermatomyositis
2
E-MTAB-62, E-GEOD-5370
head and neck squamous cell carcinoma
2
E-MTAB-62, E-GEOD-6631
Emery-Dreifuss muscular dystrophy
2
E-GEOD-3307, E-MTAB-62
265 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-1417, E-TABM-782, E-GEOD-5824, E-MEXP-941, ... (26 experiments)

Factor Value U/D Experiments
ethanol
2
E-MEXP-2241, E-GEOD-3113
placebo
1
E-MEXP-1335
ionomycin
1
E-GEOD-7307
granulocyte-colony stimulating factor
1
E-GEOD-7400
ponasterone A
1
E-GEOD-3113
filtered air
1
E-TABM-127
33 more value(s).


A rna yield

studied in E-TABM-325

Factor Value U/D Experiments
58.98
1
1
E-TABM-325


Age at onset
studied in E-GEOD-21521

Agent
studied in E-GEOD-19519

Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd38
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-TABM-234, E-GEOD-19743, E-GEOD-7967, ... (10 experiments)

Clinical info
studied in E-GEOD-19743, E-GEOD-22513, E-MEXP-1251, E-GEOD-21374, E-GEOD-1563, ... (14 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-5999, E-GEOD-1614, E-GEOD-1638, E-GEOD-20033, ... (10 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-TABM-147, E-GEOD-21138, E-GEOD-21887, ... (7 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-GEOD-7011, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, ... (9 experiments)

Genotype
studied in E-GEOD-2152, E-TABM-1029, E-GEOD-1045, E-GEOD-3494, E-GEOD-17476, ... (12 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-MEXP-2657, E-GEOD-20540, E-GEOD-837, E-MEXP-1273, ... (14 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-302, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-TABM-740, E-MEXP-2069, E-GEOD-1926, ... (38 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-MEXP-561, E-GEOD-17400 ... (5 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214, E-GEOD-12662

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Material type
studied in E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-1801, E-AFMX-1, E-GEOD-426, E-TABM-84 ... (5 experiments)

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

P53 ihc
studied in E-GEOD-21653

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-1493, E-GEOD-22309, E-GEOD-21750, E-GEOD-1657, E-GEOD-1460, ... (9 experiments)

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

Rna integrity
studied in E-TABM-325

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-1509, E-GEOD-1676, E-GEOD-3697, ... (7 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374, E-MEXP-70, E-GEOD-17400

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-19069, E-GEOD-7307

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-11428

Strain or line
studied in E-MEXP-1996, E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

tissue (organ)
studied in E-GEOD-22601

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-19815, E-GEOD-15799 ... (5 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments 00 005
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-22541, E-TABM-43, E-GEOD-1561, ... (6 experiments)

Vehicle
studied in E-GEOD-5258

weight of protein recovered
studied in E-GEOD-21918

Processing time: 0.322 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM